The days are long gone when cannabis held center stage in a bygone era’s culture wars.

Polls now show a majority of Americans support legalization. And lawmakers are responding. Forty states have legalized cannabis for either recreational or medical use. More are on the way.

Yet vestiges of old attitudes towards cannabis remain. In fact, they are embedded in federal law. The Controlled Substances Act (CSA) from the early 1970s Nixon-era keeps cannabis in what’s called Schedule I, alongside heroin and above fentanyl and cocaine.

Cannabis advocates are working hard to change that. They are making progress. The administration of President Joe Biden proposed moving cannabis to Schedule III under the CSA. President Donald Trump supported this reform in his last campaign.

The move would be a boon for cannabis companies and their stocks. It would generate large amounts of cash flow by ending a federal ban on the deduction of most expenses against revenue.

Cabot Cannabis Investor keeps subscribers up to date on the odds of favorable federal and state reform, and it singles out the best-positioned companies that would benefit the most. We follow developments at these companies like sales trends and new product lines.

Now, investing in an emerging sector like cannabis is not for everyone. Risk-averse investors will steer clear. Yet, for these investors, there’s still a great lower-risk way to get exposure to what seems like inevitable cannabis reform -- and earn income in the meantime. Chief Analyst Michael Brush has created a portfolio of companies that do not touch the plant, and instead earn money by offering loans to the sector. He makes sure the loans are well-secured by hard assets like real estate and cannabis sales licenses.

His portfolio offers an annual dividend yield in the 12% range. The portfolio was recently up 52% compared to a 22.5% gain for Russell 2000 index and a 29.4% loss for New Cannabis Ventures Global Cannabis Stock Index, since its March 2023 inception.

So, whether you are a conservative investor looking for an income portfolio with a history of outperformance, or an investor willing to take on risk to potentially benefit from ongoing federal and state reform, Cabot Cannabis Investor can serve your needs.

Download Sample Issue

As Seen On:

Michael Brush

Chief Analyst, Cabot Cannabis Investor

Michael Brush is an award-winning Manhattan-based financial writer who writes a stock market column for MarketWatch. He is editor of Brush Up on Stocks, an investment newsletter. Brush previously covered the stock market, business and economics for the New York Times, the Economist Group, MSN Money, and Money magazine.

Brush attended Columbia University Business School (Knight-Bagehot Fellowship program), and the Johns Hopkins University School of Advanced International Studies (SAIS).

He is the author of Lessons from the Front Line (published by John Wiley), a book offering investing insights based on the experiences of leading professional money managers he’s met on the job.

Brush has received several awards for excellence in journalism including the Best in Business award from the Society of American Business Editors (SABEW), the American Society of Magazine Editors’ National Magazine Award for General Excellence in New Media, and awards for excellence in local news coverage in Pennsylvania, where he started his career.